◇ V-Series Protocol
Visceral fat reduction with lean mass and dermal preservation
Every component is individually sourced and third-party verified. Tap any compound for its full clinical reference.
A weight-loss stack that also looks after lean muscle and skin. It pairs a GLP-1 based compound with growth hormone support, aimed at the muscle loss and loose skin that often come with fast weight loss.
CLINICAL INDICATION: Patients pursuing aesthetic-conscious weight management, metabolic syndrome, refractory obesity
Advanced metabolic protocol engineered to address Incretin-Induced Facial Volumetric Loss. Tirzepatide drives GLP-1/GIP dual agonism for visceral fat reduction; Tesamorelin amplifies growth hormone pulses to preserve lean mass and dermal collagen. BPC-157 can be added for people with GI sensitivity history, low body mass, or first-time GLP-1 exposure during the titration window.
Monotherapy Tirzepatide reduces fat indiscriminately, including facial fat pads and dermal support structures. V-03 addresses this clinically: Tesamorelin's GHRH analog activity preserves subcutaneous tissue and skin elasticity during weight loss. For people who experience significant GI burden during titration, BPC-157 is available as an adjunct rather than bundled as a default.
| What's in the box | Specification | Per month |
|---|---|---|
| Tirzepatide | 10mg vial · once-weekly administration covers ~4 weeks | 1× |
| Tesamorelin | 10mg vial · typical monthly allocation | 1× |
| BPC-157 | 5mg vial · 2 vials typical monthly supply for adjunct support | 2× |
GLP-1 class - Tirzepatide, Retatrutide, Semaglutide, Cagrilintide, V-03, V-M2
These protocols work on appetite, insulin sensitivity, and how your body stores fat. Monitoring tracks both the metabolic benefit and the things that change quickly during weight loss - blood sugar, lipids, and lean-mass markers.
Incremental approach. Doses are titrated upward slowly from a low starting point. Maintenance is typically a moderate dose - pushing higher rarely adds benefit and adds side effects. Monitoring guides where you settle.
Educational only - not medical advice or a dosing instruction. Your own doctor orders tests, interprets results and decides what is right for you. See the Informed Consent & Disclaimer for full terms.
Rapid GLP-1/GIP weight loss reduces fat and lean muscle. The foundation for preserving muscle is resistance training and adequate protein (roughly 1.2–1.6 g/kg/day for most people losing weight) - these do most of the work and come first.
As an adjunct, some people consider a GH-axis secretagogue stack, on the rationale that supporting the growth-hormone / IGF-1 axis may help protect lean mass during a caloric deficit. This is mechanistically reasonable but not established by combination-outcome trials - there is no study showing it preserves more muscle than training and protein alone. Whether it is appropriate is a question for your own doctor.
Educational only - not a recommendation to combine compounds or a dosing instruction.
| Biomarker | Why It's Monitored | Baseline | Cadence |
|---|---|---|---|
| HbA1c | Glycemic control and efficacy signal | Yes | Wk 6, 12 |
| Fasting insulin | Insulin-sensitivity trend | Yes | Wk 6, 12 |
| Lipid panel | Metabolic recomposition surveillance | Yes | Wk 6, 12 |
| Lean mass (DEXA) | Confirm lean-mass preservation | Yes | Wk 6, 12 |
| IGF-1 | Growth-axis surveillance when paired | Yes | Wk 6, 12 |
| GI tolerability log | Guides titration pace | Yes | Ongoing |
Phase 3 RCT over 72 weeks. Mean weight reduction was 16.0%, 21.4%, and 22.5% at 5, 10, and 15 mg respectively, versus 2.4% on placebo. Body-composition analysis showed approximately 3-fold greater fat-mass reduction than lean-mass reduction. Three-year extension data have since shown durable maintenance of weight loss when therapy is continued under supervision.
View on publisher ↗Head-to-head Phase 3 RCT in adults with type 2 diabetes inadequately controlled on metformin. Tirzepatide produced superior reductions in HbA1c and body weight compared with semaglutide 1 mg at 40 weeks. Patients on tirzepatide 15 mg had approximately twice the weight loss of those on semaglutide 1 mg, with a comparable gastrointestinal adverse-event profile. First major head-to-head incretin-class trial.
View on publisher ↗Phase 3b open-label, controlled, head-to-head trial over 72 weeks in adults with obesity but without type 2 diabetes. Tirzepatide produced superior reductions in body weight and waist circumference versus semaglutide 2.4 mg (the approved obesity dose). Gastrointestinal adverse events leading to discontinuation occurred more often with semaglutide than tirzepatide. First direct comparative obesity trial between the two agents.
View on publisher ↗Pivotal Phase 3 RCT in HIV-associated lipodystrophy over 26 weeks. Tesamorelin produced selective reduction in visceral adipose tissue versus placebo, with improvements in lipid profile and no significant glycaemic worsening at the studied dose. This trial supported the FDA approval for the lipodystrophy indication. Use outside this indication is off-label.
View on publisher ↗PRISMA-compliant systematic review (36 studies, 1993–2025) summarising the BPC-157 evidence base. The authors documented BPC-157's mechanistic profile (growth hormone receptor enhancement, angiogenesis modulation, anti-inflammatory pathways) across preclinical IBD, GI ulcer, NSAID-induced injury, fistula, and anastomotic models. Critically, the review states: "No clinical safety data is available to date" - i.e. despite extensive preclinical activity, controlled human safety and efficacy data remain absent in the modern peer-reviewed literature.
View on publisher ↗Early Croatian Phase I/II clinical trials (PL10, PL14736) explored BPC-157 in mild-to-moderate ulcerative colitis, reporting safety and tolerability signals in small cohorts. Important caveats: these trials were conducted primarily by BPC-157's discoverers and have not been independently replicated in Western peer-reviewed RCTs at scale; detailed trial reports have not appeared in major Western journals despite frequent reference in subsequent reviews. The 2024 Sikiric et al. review summarises three decades of work but is from the originating group. Independent confirmatory trials remain absent.
View on publisher ↗In-vitro study on isolated Achilles tendon fibroblasts. BPC-157 produced time- and dose-dependent upregulation of Growth Hormone Receptor expression at the mRNA and protein level, with increased fibroblast proliferation markers. Mechanistic and preclinical; does not constitute evidence of efficacy in human tissue repair.
View on publisher ↗Preclinical study mapping cellular pathways. Identified BPC-157 activity on the FAK–paxillin migration pathway, with enhanced cell outgrowth and survival in tendon-explant models. Cellular/animal level; human controlled trial evidence remains absent.
View on publisher ↗Comprehensive narrative review of BPC-157 wound-healing data across skin wounds, burns, diabetic ulcers, alkali burns, and a distinctive body of fistula-healing work (colocutaneous, gastrocutaneous, esophagocutaneous, duodenocutaneous, vesicovaginal, rectovaginal). Documents the angiogenic mechanism - BPC-157 upregulates VEGF-a and promotes endothelial proliferation and vascular tube formation, with an angiogenic effect exceeding standard agents in the sponge assay. Two important caveats: (1) the evidence is almost entirely animal (rat/mouse, some pig) - not human outcome data; (2) it is a review by the originating Zagreb group, and most primary citations are that group's own work, so it has not been independently replicated at scale. Note also that the same pro-angiogenic/VEGF action that drives healing is the basis for the theoretical oncologic caution discussed for any angiogenic compound.
View on publisher ↗Review proposing BPC-157 as a candidate for cancer cachexia (cancer-related muscle/fat wasting). In a C-26 colon-adenocarcinoma mouse model the peptide antagonised TNF-α and IL-6, cytokines central to cachexia. Preclinical and pre-clinical-trial - a proposal, not an outcome study - and from the originating (Sikiric) group.
View on publisher ↗In vitro: BPC-157 (2–10 ng) reduced human melanoma cell S-phase fraction by up to ~55% and decreased ERK phosphorylation - i.e. it acted as an antimitogenic agent INHIBITING the VEGF-MAPK proliferative signal in melanoma cells. A conference abstract (no full text), from the originating group; counterintuitive against the “BPC promotes angiogenesis” healing literature, which is why both directions matter.
View on publisher ↗A 2025 review in which the originating group directly addresses the tumour-risk speculation: it argues BPC-157 CONTROLS/MODULATES angiogenesis rather than driving tumorigenesis (e.g. it opposes corneal neovascularisation - “angiogenic privilege”), reports anti-tumour potential in vitro and in vivo per Folkman’s concept, and notes LD1 not achieved with no reported adverse effects. Important read: this is a defence authored by the compound’s originating group, so it answers but does not independently close the theoretical tumour-risk question.
View on publisher ↗Every lot is independently tested and the report is published on this page. International shipping $35, free on orders of $250 or more. Research use only, adults 21 and over.
Are you 21 years of age or older?